Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis findsBMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f2607 (Published 23 April 2013) Cite this as: BMJ 2013;346:f2607
- Deborah Cohen
A class of antidiabetes drugs is associated with an increase in safety alerts for pancreatitis and pancreatic cancer, a new analysis has found.
The Institute for Safe Medication Practices, a US non-profit organisation that promotes the safe use of drugs, monitored reports of serious adverse events to the US Food and Drug Administration from 1 July 2011 to 30 June 2012 concerning five glucagon-like peptide-1 (GLP-1) based agents (exenatide, liraglutide, sitagliptin, saxagliptin, and linagliptin) used to lower blood glucose concentrations.
It compared these against the rates of adverse event reporting for a control group of drugs comprising other drugs used to treat type 2 diabetes (three sulfonylureas and metformin) and drugs for treating other diseases.
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.